Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults (Polaris)

2026. augusztus 21. frissítette: argenx

A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult and Adolescent Participants With Autoimmune Encephalitis

The POLARIS study is designed to evaluate how well efgartigimod PH20 SC may work (called "efficacy") and how safe it is for people diagnosed with Autoimmune Encephalitis (AIE). The study consists of 4 parts: in part A participants will receive efgartigimod SC; in part B, participants will be randomized to receive either efgartigimod SC or placebo; in part C, participants who completed part B will receive efgartigimod SC; in part D, participants who completed part C will be observed after their last dose of efgartigimod SC. If AIE symptoms return, efgartigimod SC treatment may be restarted during this time.

The maximum overall study duration for participants is up to 3 years. More information can be found in clinicaltrials.argenx.com/polaris

A tanulmány áttekintése

Állapot

Toborzás

Körülmények

Beavatkozás / kezelés

Részletes leírás

The study is designed to address the unmet need for effective immunomodulatory therapy in AIE, enrolling patients across multiple antibody-defined subgroups, with the anti-NMDAR encephalitis group serving as the primary cohort for statistical analysis.

Tanulmány típusa

Beavatkozó

Beiratkozás (Becsült)

170

Fázis

  • 2. fázis

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi kapcsolat

Tanulmányi helyek

  • Egyesült Államok
    • Arizona
      • Tucson, Arizona, Egyesült Államok, 85718
        • Toborzás
        • Center For Neurosciences
        • Kutatásvezető:
          • Francisco Valdivia
        • Kapcsolatba lépni:
    • Texas
      • Sherman, Texas, Egyesült Államok, 75092-7371
        • Toborzás
        • Texas Institute for Neurological Disorders
        • Kutatásvezető:
          • Bharathy Sundaram
        • Kapcsolatba lépni:

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

  • Gyermek
  • Felnőtt
  • Idősebb felnőtt

Egészséges önkénteseket fogad

Nem

Leírás

Inclusion Criteria:

  • Is at least 12 years of age.
  • Meeting at least the criteria for possible AIE according to the Graus criteria.
  • Part A:

Must not have received prior treatment for AIE with PLEX or Ig (participants may have received glucocorticoids); and must not have received PLEX or Ig for any other medical condition in the last 3 months

- Part B: Either completing Part A, or If directly entering Part B, must have received first-line treatment for AIE (i.e. corticosteroids, PLEX, and/or Ig) and have a CASE score of 3 or higher, or a score of 2 or higher in a single sub-item

Exclusion Criteria:

  • Known anti-myelin oligodendrocyte glycoprotein (anti-MOG) antibody positivity.
  • Any medical condition that would interfere with an accurate assessment of clinical symptoms of AIE.
  • Recent major surgery (within 3 months of screening) or intention to have major surgery during the study, except for surgeries for AIE-related teratomas and thymomas.
  • History (within 12 months before screening) of current alcohol, drug (including recreational or prescribed cannabinoids), or medication abuse.
  • Psychiatric or cognitive impairment unrelated to AIE.

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Kezelés
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Párhuzamos hozzárendelés
  • Maszkolás: Hármas

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: Part A (Open-Label Lead-in Period): Efgartigimod PH20 SC
All participants will receive efgartigimod PH20 SC open label for 8 weeks
Biológiai: Efgartigimod PH20 (ARGX-113) SC
subcutaneous administrations of efgartigimod PH20 SC given by prefilled syringe (PFS). For participants aged 12 to <18 years with body weight ≤50 kg, the study drug will be administered by vial and syringe.
Kísérleti: Part B (Double-blinded treatment period): Efgartigimod PH20 SC
Participants will receive efgartigimod PH20 SC for 24 weeks
Biológiai: Efgartigimod PH20 (ARGX-113) SC
subcutaneous administrations of efgartigimod PH20 SC given by prefilled syringe (PFS). For participants aged 12 to <18 years with body weight ≤50 kg, the study drug will be administered by vial and syringe.
Placebo Comparator: Part B (Maintenance double-blinded treatment period): Placebo PH20 SC
Participants will receive placebo for 24 weeks
Egyéb: Placebo PH20 SC

subcutaneous administrations of placebo PH20 SC given by prefilled syringe (PFS). For participants aged 12 to <18 years with body weight

≤50 kg, the study drug will be administered by vial and syringe
Kísérleti: Part C (Open-Label Extension Period): Efgartigimod PH20 SC
Participants who complete Part B will receive efgartigimod PH20 SC for 24 weeks
Biológiai: Efgartigimod PH20 (ARGX-113) SC
subcutaneous administrations of efgartigimod PH20 SC given by prefilled syringe (PFS). For participants aged 12 to <18 years with body weight ≤50 kg, the study drug will be administered by vial and syringe.

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Change in CASE score in the NMDAR population
Időkeret: up to week 24
CASE= Clinical Assessment Scale in Autoimmune Encephalitis; NMDAR=N-methyl-D-aspartate receptor; Neuropsychological Status. The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
up to week 24

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Change in mRS
Időkeret: up to week 8
The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities. Scores range from 0 (no symptoms) to 6(dead).
up to week 8
Change in CASE score
Időkeret: up to week 8
The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
up to week 8
Change in MoCA total score
Időkeret: up to week 8
MoCA= Montreal Cognitive Assessment
up to week 8
Change in NPI-C total score
Időkeret: up to week 8
The NPI-C (Neuropsychiatric Inventory--Clinician) total score will be used as a global measure of neuropsychiatric symptoms.Total score is calculated by summing the scores of all the individual domains.Each domain score is determined by summing the item scores within that domain. The NPI-C uses a clinician rating method, where ratings for frequency, severity, and caregiver distress are provided for each item.These item scores are then summed to create a total domain score.
up to week 8
Change from baseline in CGI-S
Időkeret: up to week 8

Expression of Change. CGI is a clinician-rated scale that measures illness severity (CGI-S) and global improvement or change (CGI-C).It is rated on a 7-point scale, from 1 (normal) to 7 (amongst the most severely ill patients) for CGI-S and from 1 (very much improved) to 7 (very much worse) for CGI-C.

PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
up to week 8
Change from baseline in PGI-S
Időkeret: up to week 8
A Impression of Severity; PGI-S= Patient Global Impression Scale. PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
up to week 8
Change from baseline in CGI-C
Időkeret: up to week 8

CGI-C= Clinical Global Expression of Change . CGI is a clinician-rated scale that measures illness severity (CGI-S) and global improvement or change (CGI-C).It is rated on a 7-point scale, from 1 (normal) to 7 (amongst the most severely ill patients) for CGI-S and from 1 (very much improved) to 7 (very much worse) for CGI-C.

PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
up to week 8
Change from baseline in PGI-C
Időkeret: up to week 8
A Impression of Severity; PGI-C= Patient Global Expression of Change . PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
up to week 8
Incidence and severity of AEs
Időkeret: up to week 8
AEs= Adverse Effects
up to week 8
Incidence and severity of SAEs
Időkeret: up to week 8
SAEs = Serious Adverse Effects
up to week 8
Trough efgartigimod serum concentrations over time
Időkeret: up to week 8
up to week 8
Percent change from baseline in total IgG levels in serum over time
Időkeret: up to week 8
IgG= Immunoglobulin G
up to week 8
Incidence and prevalence of ADA against efgartigimod in serum over time
Időkeret: up to week 8
ADA = antidrug antibody(ies)
up to week 8
Incidence and prevalence of antibodies against rHuPH20 in plasma over time
Időkeret: up to week 8
rHuPH20 = Recombinant Human Hyaluronidase PH20
up to week 8
Change in mRS in the NMDAR population
Időkeret: up to week 24
The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities. Scores range from 0 (no symptoms) to 6(dead)
up to week 24
Change in NPI-C total score in the NMDAR population
Időkeret: up to week 24
NPI-C=Neuropsychiatric Inventory-Clinician; NMDAR=N-methyl-D-aspartate receptor. The NPI-C (Neuropsychiatric Inventory--Clinician) total score will be used as a global measure of neuropsychiatric symptoms. Total score is calculated by summing the scores of all the individual domains. Each domain score is determined by summing the item scores within that domain. The NPI-C uses a clinician rating method, where ratings for frequency, severity, and caregiver distress are provided for each item.These item scores are then summed to create a total domain score.
up to week 24
Change in RBANS in the NMDAR population
Időkeret: up to week 24
RBANS=Repeatable Battery for the Assessment of Neuropsychological Status; NMDAR=N-methyl-D-aspartate receptor. The RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is a performance outcome measure developed to identify and characterize cognitive impairment by assessing an individual's current level of cognitive performance.
up to week 24
Percentage of CASE responders in the NMDAR population.
Időkeret: at week 24
CASE = Clinical Assessment Scale in AIE ; NMDAR=N-methyl-D-aspartate receptor
at week 24
Change in CASE score in the non-NMDAR population
Időkeret: up to week 24
CASE = Clinical Assessment Scale in AIE; NMDAR=N-methyl. The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure,memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
up to week 24
Change in RBANS in the non-NMDAR population
Időkeret: up to week 24
RBANS= Repeatable Battery for the Assessment of Neuropsychological Status; NMDAR=N-methyl-D-aspartate receptor. The RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is a performance outcome measure developed to identify and characterize cognitive impairment by assessing an individual's current level of cognitive performance.
up to week 24
Change in NPI-C total score in the non-NMDAR population
Időkeret: up to week 24
NPI-C= Neuropsychiatric Inventory-Clinician; NMDAR=N-methyl-D-aspartate receptor. The NPI-C Neuropsychiatric Inventory--Clinician) total score will be used as a global measure of neuropsychiatric symptoms. Total score is calculated by summing the scores of all the individual domains. Each domain score is determined by summing the item scores within that domain. The NPI-C uses a clinician rating method, where ratings for frequency, severity, and caregiver distress are provided for each item.
up to week 24
Change in mRS in the non-NMDAR population
Időkeret: up to week 24
mRS= modified Rankin Scale; NMDAR=N-methyl-D-aspartate receptor. The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities.Scores range from 0 (no symptoms) to 6 (dead).
up to week 24
Percentage of CASE responders in the non-NMDAR population.
Időkeret: at week 24
CASE = Clinical Assessment Scale in AIE ; NMDAR=N-methyl-D-aspartate receptor. The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
at week 24
Incidence and severity of AEs
Időkeret: week 24 onwards
AEs = Adverse Effects
week 24 onwards
Incidence and severity of SAEs
Időkeret: week 24 onwards
SAEs = Serious Adverse Effects
week 24 onwards
Proportion of participants with presence of neuropsychiatric symptoms, defined by NPI-C total score of at least 1 point
Időkeret: at week 24
NPI-C= Neuropsychiatric Inventory-Clinician. The NPI-C (Neuropsychiatric Inventory--Clinician) total score will be used as a global measure of neuropsychiatric symptoms. Total score is calculated by summing the scores of all the individual domains. Each domain score is determined by summing the item scores within that domain. The NPI-C uses a clinician rating method, where ratings for frequency, severity, and caregiver distress are provided for each item.
at week 24
Change in MoCA total score
Időkeret: up to week 24
MoCA= Montreal Cognitive Assessment
up to week 24
Proportion of participants with a favorable outcome in mRS where favorable outcome is defined as no worsening for participants with a baseline mRS score of ≤2 or improvement of ≥1 point for participants with a baseline mRS score of >2
Időkeret: up to week 24
mRS=modified Rankin Scale. The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities. Scores range from 0 (no symptoms) to 6 (dead).
up to week 24
Change in CGI-S
Időkeret: up to week 24
CGI-S= Clinical Global Impression of Severity. CGI is a clinician-rated scale that measures illness severity (CGI-S) and global improvement or change (CGI-C).It is rated on a 7-point scale, from 1 (normal) to 7 (amongst the most severely ill patients) for CGI-S and from 1 (very much improved) to 7 (very much worse) for CGI-C.
up to week 24
Change in CGI-C
Időkeret: up to week 24
CGI-C= Clinical Global Impression of Change. CGI is a clinician-rated scale that measures illness severity (CGI-S) and global improvement or change (CGI-C).It is rated on a 7-point scale, from 1 (normal) to 7 (amongst the most severely ill patients) for CGI-S and from 1 (very much improved) to 7 (very much worse) for CGI-C.
up to week 24
Change in PGI-C
Időkeret: week 0 to week 24
PGI-C =Patient Global Expression of Change. PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
week 0 to week 24
Change in PGI-S
Időkeret: week 0 to week 24
PGI-S= Patient Global Expression of Severity. PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
week 0 to week 24
Time to resolution of status epilepticus
Időkeret: up to 24 weeks
up to 24 weeks
Time to first occurrence of seizure freedom.
Időkeret: up to 24 weeks
Seizure freedom is defined as no seizures for at least 28 consecutive days
up to 24 weeks
Proportion of participants with seizure freedom for at least the 28 consecutive days
Időkeret: up to 24 weeks
up to 24 weeks
Time to use of rescue therapy after randomization
Időkeret: up to 24 weeks
up to 24 weeks
Trough efgartigimod serum concentrations over time
Időkeret: up to 24 weeks
up to 24 weeks
Percent change in total IgG levels in serum
Időkeret: up to 24 weeks
IgG = Immunoglobulin G
up to 24 weeks
Incidence and prevalence of ADA against efgartigimod in serum over time
Időkeret: up to 24 weeks
ADA = anti drug antibodies
up to 24 weeks
Incidence and prevalence of antibodies against rHuPH20 in plasma over time
Időkeret: up to 24 weeks
rHuPH20 = Recombinant Human Hyaluronidase PH20
up to 24 weeks
Change in CASE score in the NMDAR population compared with the non-NMDAR population
Időkeret: up to 24 weeks
CASE = Clinical Assessment Scale in AIE ; NMDAR=N-methyl-D-aspartate receptor. . The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
up to 24 weeks
Change in RBANS total score
Időkeret: week 24 to week 48
The RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is a performance outcome measure developed to identify and characterize cognitive impairment by assessing an individual's current level of cognitive performance.
week 24 to week 48
Percentage of participants with maintained change in the CASE total score (defined as stable or improving)
Időkeret: week 24 to week 48
The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
week 24 to week 48
Percentage of participants with maintained mRS score (defined as stable or improving)
Időkeret: week 24 to week 48
The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities. Scores range from 0 (no symptoms) to 6 (dead).
week 24 to week 48
Change in NPI-C total score
Időkeret: week 24 to week 48
The NPI-C (Neuropsychiatric Inventory--Clinician) total score will be used as a global measure of neuropsychiatric symptoms.Total score is calculated by summing the scores of all the individual domains. Each domain score is determined by summing the item scores within that domain. The NPI-C uses a clinician rating method, where ratings for frequency, severity, and caregiver distress are provided for each item. These item scores are then summed to create a total domain score.
week 24 to week 48
Proportion of participants requiring rescue or second-line AIE therapies
Időkeret: week 24 to week 48
AIE = Auto-Immune Encephalitis
week 24 to week 48
Time to participants requiring rescue or second-line AIE therapies
Időkeret: week 24 to week 48
AIE = Auto-Immune Encephalitis
week 24 to week 48
Change in CASE
Időkeret: week 24 to week 48
The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
week 24 to week 48
Change in mRs
Időkeret: week 24 to week 48
The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities. Scores range from 0 (no symptoms) to 6 (dead).
week 24 to week 48
Change in RBANS
Időkeret: week 24 to week 48
The RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is a performance outcome measure developed to identify and characterize cognitive impairment by assessing an individual's current level of cognitive performance.
week 24 to week 48
Time to resolution of status epilepticus
Időkeret: week 24 to week 48
week 24 to week 48
Proportion of participants with seizure freedom for at least the 28 consecutive days preceding the participants in final Part of trial
Időkeret: week 24 to week 48
mRS=modified Rankin Scale
week 24 to week 48
Incidence and prevalence of ADA against efgartigimod in serum
Időkeret: week 24 to week 48
ADA = antidrug antibody(ies)
week 24 to week 48
Percent change in total IgG levels in serum
Időkeret: week 24 to week 48
IgG = Immunoglobulin G
week 24 to week 48

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Szponzor

argenx

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Becsült)

2026. augusztus 15.

Elsődleges befejezés (Becsült)

2029. január 20.

A tanulmány befejezése (Becsült)

2029. május 12.

Tanulmányi regisztráció dátumai

Először benyújtva

2026. május 7.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2026. május 7.

Első közzététel (Tényleges)

2026. május 13.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. augusztus 24.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. augusztus 21.

Utolsó ellenőrzés

2026. május 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Kulcsszavak

További vonatkozó MeSH feltételek

Egyéb vizsgálati azonosító számok

  • ARGX-113-22-AIE-2001

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

NEM

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Igen

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel